Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone781-457-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$105.56 million
Profitability
Miscellaneous
Employees133
Next Earnings Date7/24/2019 (Estimated)
OptionableOptionable
Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc (NASDAQ:ANIK) released its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.10. The biotechnology company had revenue of $24.72 million for the quarter, compared to analyst estimates of $22.06 million. Anika Therapeutics had a return on equity of 11.57% and a net margin of 27.44%. The business's revenue was up 16.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.46) earnings per share. View Anika Therapeutics' Earnings History.
When is Anika Therapeutics' next earnings date?
What price target have analysts set for ANIK?
4 Wall Street analysts have issued twelve-month price targets for Anika Therapeutics' stock. Their forecasts range from $35.00 to $44.00. On average, they anticipate Anika Therapeutics' share price to reach $38.6667 in the next year. This suggests a possible upside of 1.5% from the stock's current price. View Analyst Price Targets for Anika Therapeutics.
What is the consensus analysts' recommendation for Anika Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics.
Has Anika Therapeutics been receiving favorable news coverage?
News coverage about ANIK stock has trended somewhat negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Anika Therapeutics earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Nevro (NVRO), Atrion (ATRI), Irhythm Technologies (IRTC), Shockwave Medical (SWAV), Mazor Robotics (MZOR), Silk Road Medical (SILK), Cardiovascular Systems (CSII), K2M Group (KTWO), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Luminex (LMNX), Tactile Systems Technology (TCMD), Axonics Modulation Technologies (AXNX) and Intersect ENT (XENT).
What other stocks do shareholders of Anika Therapeutics own?
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
- Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
- Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
- Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)
- Mr. Alexei Goraltchouk, VP of Operations
Who are Anika Therapeutics' major shareholders?
Anika Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.97%), Kayne Anderson Rudnick Investment Management LLC (11.30%), Dimensional Fund Advisors LP (7.21%), Renaissance Technologies LLC (2.57%), BTIM Corp. (1.85%) and Wells Fargo & Company MN (1.54%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Joseph G Darling, Raymond J Land and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.
Which major investors are selling Anika Therapeutics stock?
ANIK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Assenagon Asset Management S.A., THB Asset Management, Oxford Asset Management LLP, Los Angeles Capital Management & Equity Research Inc., Parametric Portfolio Associates LLC, Gabelli Funds LLC and Citigroup Inc.. View Insider Buying and Selling for Anika Therapeutics.
Which major investors are buying Anika Therapeutics stock?
ANIK stock was acquired by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Renaissance Technologies LLC, Morgan Stanley, Hotchkis & Wiley Capital Management LLC, Hotchkis & Wiley Capital Management LLC, Bank of Montreal Can, Acadian Asset Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Anika Therapeutics.
How do I buy shares of Anika Therapeutics?
Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of ANIK stock can currently be purchased for approximately $38.09.
How big of a company is Anika Therapeutics?
Anika Therapeutics has a market capitalization of $541.14 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.
What is Anika Therapeutics' official website?
How can I contact Anika Therapeutics?
Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]
MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
